Pharma & Biotech IP Connect, which is a virtual iam event, is held from 14^th – 15^th April 2021. The event brings together leading in-house practitioners and expert outside counsels to explore the most important IP trends impacting the industry and focus on discussion concerning how IP professionals can best adapt their approaches to protecting and commercialising their clients’ innovations.

The Asia-Pacific session of the event features four panel discussions spreading over two days, covering topics including “How many patents do you need?”, “Patent update bulletin”, “Collaboration class – working with partners” and “Patent playbook Asia”.

Rui Wang, Partner of Wanhuida Intellectual Property speaks on “Patent linkage in China – what shape is it taking?” at the “Patent update bulletin” panel on April 14. Speakers examine how recent news and judgments are impacting Asia’s life sciences industry. Fellow panelists include Mahendra Gunjal, Manager, Global IP, Zydus Group, have productive discussion on “The state of play for biologics and biosimilars” and “More highlights from the international landscape and how they will impact APAC players”.

Rui Wang speaking at the panel discussion